Frontlight ResearchEarly access
Not yet recruitingPhase 2
Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma.
Key facts
- Who runs it
- Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 32 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 30 Sept 2033
- Type of study
- Interventional
- Record updated
- 2 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Male and females ≥18 years of age
- Patients with preoperative diagnosis of ACC ENS@T stage II or III
- No previous treatments for ACC except for mitotane
- Multidisciplinary indication to upfront surgery
- Women of child-bearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of study
- Women must not be breastfeeding
- Willing and able to comply with clinic visits and study-related procedures
- Willing and able to provide informed consent signed by study patient or legally acceptable representative
Who cannot take part
- If the histological diagnosis after surgery will indicate a tumor histotype other than ACC, the patient will be dropped from the study
- Intercurrent clinical conditions, such as uncontrolled infections or heart failure, that prevent the surgical procedure from being performed
- Patients with extensive inferior vena cava thrombosis requiring vascular replacement or extracorporeal circulation procedures
- Exploratory procedures or procedure conducted not according to the technical guidelines for regional adrenalectomy
- Diagnosis other than ACC at histological examination
- Patients with ENS@T stage I or IV tumors
- Patients with ad ECOG performance status >1
- Pregnancy
- Continued sexual activity in women of childbearing potential or sexually active men who are unwilling to practice highly effective contraception (including at least one highly effective contraception method, see study protocol) for at least 6 months after the HIPEC
- Refusal to sign the informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluation of the impact of HIPEC on the incidence of local or peritoneal recurrences of ACC, assessed through clinical examinations, blood biochemical tests, and thoraco-abdominal CT scan (with and without contrast) performed every 4 months, according to standard clinical practice.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma
- Record updated
- 2 September 2026